{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:14:59Z","timestamp":1794413699603,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270892"],"award-info":[{"award-number":["32270892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200613"],"award-info":[{"award-number":["32200613"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60039-2","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:21:25Z","timestamp":1747736485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases"],"prefix":"10.1038","volume":"16","author":[{"given":"Ruixin","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-4610","authenticated-orcid":false,"given":"Sijin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8010-3084","authenticated-orcid":false,"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-3781","authenticated-orcid":false,"given":"Chenghao","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3460-6716","authenticated-orcid":false,"given":"Haiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3131-7804","authenticated-orcid":false,"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-6948","authenticated-orcid":false,"given":"Songbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"60039_CR1","doi-asserted-by":"publisher","first-page":"e2201740","DOI":"10.1002\/advs.202201740","volume":"9","author":"M Luo","year":"2022","unstructured":"Luo, M. et al. Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases. Adv. Sci. 9, e2201740 (2022).","journal-title":"Adv. Sci."},{"key":"60039_CR2","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2217\/nnm-2016-0240","volume":"11","author":"L Kong","year":"2016","unstructured":"Kong, L., Wu, Y., Alves, C. S. & Shi, X. Efficient delivery of therapeutic siRNA into glioblastoma cells using multifunctional dendrimer-entrapped gold nanoparticles. Nanomedicine 11, 3103\u20133115 (2016).","journal-title":"Nanomedicine"},{"key":"60039_CR3","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.2147\/IJN.S241055","volume":"15","author":"N Grafals-Ruiz","year":"2020","unstructured":"Grafals-Ruiz, N. et al. Brain targeted gold liposomes improve RNAi delivery for glioblastoma. Int J. Nanomed. 15, 2809\u20132828 (2020).","journal-title":"Int J. Nanomed."},{"key":"60039_CR4","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s13311-022-01283-y","volume":"19","author":"F Rofo","year":"2022","unstructured":"Rofo, F. et al. A brain-targeting bispecific-multivalent antibody clears soluble Amyloid-beta aggregates in Alzheimer\u2019s disease mice. Neurotherapeutics 19, 1588\u20131602 (2022).","journal-title":"Neurotherapeutics"},{"key":"60039_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05008-x","volume":"22","author":"N Jagadeesan","year":"2024","unstructured":"Jagadeesan, N. et al. Modulation of hippocampal protein expression by a brain penetrant biologic TNF-\u03b1 inhibitor in the 3xTg Alzheimer\u2019s disease mice. J. Transl. Med. 22, 291 (2024).","journal-title":"J. Transl. Med."},{"key":"60039_CR6","doi-asserted-by":"publisher","first-page":"E6147","DOI":"10.1073\/pnas.1701911114","volume":"114","author":"D Yu","year":"2017","unstructured":"Yu, D. et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc. Natl. Acad. Sci. USA 114, E6147\u2013e6156 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60039_CR7","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/nn506248s","volume":"9","author":"ZR Cohen","year":"2015","unstructured":"Cohen, Z. R. et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9, 1581\u20131591 (2015).","journal-title":"ACS Nano"},{"key":"60039_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1039\/c3tb21394c","volume":"2","author":"G Tian","year":"2014","unstructured":"Tian, G. et al. Engineered design of theranostic upconversion nanoparticles for tri-modal upconversion luminescence\/magnetic resonance\/X-ray computed tomography imaging and targeted delivery of combined anticancer drugs. J. Mater. Chem. B 2, 1379\u20131389 (2014).","journal-title":"J. Mater. Chem. B"},{"key":"60039_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejpb.2016.01.009","volume":"101","author":"K Gadkar","year":"2016","unstructured":"Gadkar, K. et al. Mathematical PKPD and safety model of bispecific TfR\/BACE1 antibodies for the optimization of antibody uptake in brain. Eur. J. Pharm. Biopharm. 101, 53\u201361 (2016).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"60039_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.0b013e3181ccc732","volume":"74","author":"T Van Langenhove","year":"2010","unstructured":"Van Langenhove, T. et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74, 366\u2013371 (2010).","journal-title":"Neurology"},{"key":"60039_CR11","doi-asserted-by":"publisher","first-page":"102270","DOI":"10.1016\/j.pneurobio.2022.102270","volume":"214","author":"U Sengupta","year":"2022","unstructured":"Sengupta, U. & Kayed, R. Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog. Neurobiol. 214, 102270 (2022).","journal-title":"Prog. Neurobiol."},{"key":"60039_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1474-4422(10)70195-2","volume":"9","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie, I. R., Rademakers, R. & Neumann, M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995\u20131007 (2010).","journal-title":"Lancet Neurol."},{"key":"60039_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00415-009-5404-z","volume":"257","author":"H Seelaar","year":"2010","unstructured":"Seelaar, H. et al. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J. Neurol. 257, 747\u2013753 (2010).","journal-title":"J. Neurol."},{"key":"60039_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-019-0658-x","volume":"7","author":"H An","year":"2019","unstructured":"An, H. et al. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 7, 7 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"60039_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40478-016-0358-8","volume":"4","author":"M Nolan","year":"2016","unstructured":"Nolan, M., Talbot, K. & Ansorge, O. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol. Commun. 4, 99 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"60039_CR16","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1093\/hmg\/ddt328","volume":"22","author":"M Sabatelli","year":"2013","unstructured":"Sabatelli, M. et al. Mutations in the 3\u2019 untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 22, 4748\u20134755 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"60039_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-012-1043-z","volume":"125","author":"JC Mitchell","year":"2013","unstructured":"Mitchell, J. C. et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 125, 273\u2013288 (2013).","journal-title":"Acta Neuropathol."},{"key":"60039_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104\u2013116 (2022).","journal-title":"Nat. Med."},{"key":"60039_CR19","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"60039_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tips.2023.05.008","volume":"44","author":"Z Yang","year":"2023","unstructured":"Yang, Z., Pang, Q., Zhou, J., Xuan, C. & Xie, S. Leveraging aptamers for targeted protein degradation. Trends Pharm. Sci. 44, 776\u2013785 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"60039_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai, J. M., Nowak, R. P., Ebert, B. L. & Fischer, E. S. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol. 25, 740\u2013757 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"60039_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","volume":"27","author":"J Qu","year":"2020","unstructured":"Qu, J. et al. Specific knockdown of \u03b1-Synuclein by peptide-directed proteasome degradation rescued its associated neurotoxicity. Cell Chem. Biol. 27, 751\u2013762.e754 (2020).","journal-title":"Cell Chem. Biol."},{"key":"60039_CR23","doi-asserted-by":"publisher","unstructured":"Ge R. X. et al. Targeting neurodegenerative disease-associated protein aggregation with proximity-inducing modalities. Acta Pharmacol. Sin. https:\/\/doi.org\/10.1038\/s41401-025-01538-2 (2025).","DOI":"10.1038\/s41401-025-01538-2"},{"key":"60039_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","volume":"165-166","author":"R Pandit","year":"2020","unstructured":"Pandit, R., Chen, L. & G\u00f6tz, J. The blood-brain barrier: physiology and strategies for drug delivery. Adv. Drug Deliv. Rev. 165-166, 1\u201314 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"60039_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jconrel.2014.06.017","volume":"190","author":"X Yi","year":"2014","unstructured":"Yi, X., Manickam, D. S., Brynskikh, A. & Kabanov, A. V. Agile delivery of protein therapeutics to CNS. J. Control Release 190, 637\u2013663 (2014).","journal-title":"J. Control Release"},{"key":"60039_CR26","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","volume":"69","author":"L Kong","year":"2024","unstructured":"Kong, L. et al. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer. Sci. Bull. 69, 2122\u20132135 (2024).","journal-title":"Sci. Bull."},{"key":"60039_CR27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1021\/acs.jmedchem.2c01557","volume":"66","author":"M Chen","year":"2023","unstructured":"Chen, M. et al. Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC. J. Med. Chem. 66, 1339\u20131348 (2023).","journal-title":"J. Med. Chem."},{"key":"60039_CR28","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1021\/jacs.1c03852","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. TF-PROTACs enable targeted degradation of transcription factors. J. Am. Chem. Soc. 143, 8902\u20138910 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"60039_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102555","volume":"8","author":"J Shao","year":"2021","unstructured":"Shao, J. et al. Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): Effective targeting of LEF1 and ERG. Adv. Sci. 8, e2102555 (2021).","journal-title":"Adv. Sci."},{"key":"60039_CR30","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1074\/jbc.M008304200","volume":"276","author":"A Lerga","year":"2001","unstructured":"Lerga, A. et al. Identification of an RNA binding specificity for the potential splicing factor TLS. J. Biol. Chem. 276, 6807\u20136816 (2001).","journal-title":"J. Biol. Chem."},{"key":"60039_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1101\/gad.335836.119","volume":"34","author":"YL Tsai","year":"2020","unstructured":"Tsai, Y. L. et al. ALS\/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 34, 785\u2013805 (2020).","journal-title":"Genes Dev."},{"key":"60039_CR32","doi-asserted-by":"publisher","first-page":"e1005357","DOI":"10.1371\/journal.pgen.1005357","volume":"11","author":"J Deng","year":"2015","unstructured":"Deng, J. et al. FUS interacts with HSP60 to promote mitochondrial famage. PLoS Genet. 11, e1005357 (2015).","journal-title":"PLoS Genet."},{"key":"60039_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2174\/1566523223666221108113330","volume":"23","author":"R Kumar","year":"2023","unstructured":"Kumar, R. et al. Amyotrophic lateral sclerosis risk genes and suppressor. Curr. Gene Ther. 23, 148\u2013162 (2023).","journal-title":"Curr. Gene Ther."},{"key":"60039_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41420-022-00969-8","volume":"8","author":"YW Wang","year":"2022","unstructured":"Wang, Y. W. et al. HIF-1\u03b1-regulated lncRNA-TUG1 promotes mitochondrial dysfunction and pyroptosis by directly binding to FUS in myocardial infarction. Cell Death Discov. 8, 178 (2022).","journal-title":"Cell Death Discov."},{"key":"60039_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00401-010-0764-0","volume":"121","author":"IR Mackenzie","year":"2011","unstructured":"Mackenzie, I. R. et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 121, 207\u2013218 (2011).","journal-title":"Acta Neuropathol."},{"key":"60039_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ene.13412","volume":"25","author":"AB Deutschl\u00e4nder","year":"2018","unstructured":"Deutschl\u00e4nder, A. B., Ross, O. A., Dickson, D. W. & Wszolek, Z. K. Atypical parkinsonian syndromes: a general neurologist\u2019s perspective. Eur. J. Neurol. 25, 41\u201358 (2018).","journal-title":"Eur. J. Neurol."},{"key":"60039_CR37","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1038\/emboj.2012.261","volume":"31","author":"D Dormann","year":"2012","unstructured":"Dormann, D. et al. Arginine methylation next to the PY-NLS modulates transportin binding and nuclear import of FUS. EMBO J. 31, 4258\u20134275 (2012).","journal-title":"EMBO J."},{"key":"60039_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner, J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49\u201360 (2014).","journal-title":"Neuron"},{"key":"60039_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40681-4","volume":"14","author":"KS Chew","year":"2023","unstructured":"Chew, K. S. et al. CD98hc is a target for brain delivery of biotherapeutics. Nat. Commun. 14, 5053 (2023).","journal-title":"Nat. Commun."},{"key":"60039_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.biomaterials.2015.04.037","volume":"62","author":"MG Kim","year":"2015","unstructured":"Kim, M. G., Park, J. Y., Shim, G., Choi, H. G. & Oh, Y. K. Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62, 155\u2013163 (2015).","journal-title":"Biomaterials"},{"key":"60039_CR41","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1021\/acsnano.6b01415","volume":"10","author":"B Esteban-Fern\u00e1ndez de \u00c1vila","year":"2016","unstructured":"Esteban-Fern\u00e1ndez de \u00c1vila, B. et al. Acoustically propelled nanomotors for intracellular siRNA delivery. ACS Nano 10, 4997\u20135005 (2016).","journal-title":"ACS Nano"},{"key":"60039_CR42","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest 128, 3558\u20133567 (2018).","journal-title":"J. Clin. Invest"},{"key":"60039_CR43","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"60039_CR44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar, M. et al. Design of a randomized, placebo-controlled, Phase 3 Trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS Study. Neurotherapeutics 19, 1248\u20131258 (2022).","journal-title":"Neurotherapeutics"},{"key":"60039_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib12030043","volume":"12","author":"T Tashima","year":"2023","unstructured":"Tashima, T. Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. Antibodies 12, 43 (2023).","journal-title":"Antibodies"},{"key":"60039_CR46","doi-asserted-by":"publisher","first-page":"e2305625120","DOI":"10.1073\/pnas.2305625120","volume":"120","author":"P Mohanty","year":"2023","unstructured":"Mohanty, P. et al. A synergy between site-specific and transient interactions drives the phase separation of a disordered, low-complexity domain. Proc. Natl. Acad. Sci. USA 120, e2305625120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60039_CR47","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.cell.2015.07.047","volume":"162","author":"A Patel","year":"2015","unstructured":"Patel, A. et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell 162, 1066\u20131077 (2015).","journal-title":"Cell"},{"key":"60039_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42233-2","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Expanding PROTACtable genome universe of E3 ligases. Nat. Commun. 14, 6509 (2023).","journal-title":"Nat. Commun."},{"key":"60039_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57823-5","volume":"16","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Identification of a non-inhibitory aptameric ligand to CRL2(ZYG11B) E3 ligase for targeted protein degradation. Nat. Commun. 16, 2494 (2025).","journal-title":"Nat. Commun."},{"key":"60039_CR50","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/brain\/awp214","volume":"132","author":"M Neumann","year":"2009","unstructured":"Neumann, M. et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922\u20132931 (2009).","journal-title":"Brain"},{"key":"60039_CR51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00401-009-0598-9","volume":"118","author":"DG Munoz","year":"2009","unstructured":"Munoz, D. G. et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617\u2013627 (2009).","journal-title":"Acta Neuropathol."},{"key":"60039_CR52","doi-asserted-by":"crossref","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 9, eaag0481 (2017).","DOI":"10.1126\/scitranslmed.aag0481"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60039-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:07:14Z","timestamp":1747739234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60039"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60039-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Z. and S.X. declare the filing of a patent application for the FRONTACFUS technology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4683"}}